» Articles » PMID: 25811791

Inhibitory Mechanisms of Celastrol on Human Liver Cytochrome P450 1A2, 2C19, 2D6, 2E1 and 3A4

Overview
Journal Xenobiotica
Publisher Informa Healthcare
Specialties Biochemistry
Toxicology
Date 2015 Mar 27
PMID 25811791
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

1. The present study was conducted to examine the possibility of herb-drug interaction by celastrol, which is a main compound isolated from Tripterygium wilfordii Hook F. using human liver microsomes with cocktail methods. Focused on its inhibitory manner on the metabolism of model probe substrates of five cytochrome P450 isoenzymes (CYP1A2, CYP2C19, CYP2D6, CYP2E1 and CYP3A4) in vitro which are important with the metabolism of different xenobiotics. 2. The results showed that celastrol inhibited the five types of human cytochrome P450 isoforms, with the IC50 values of 2.65 μM (CYP3A4), 5.99 μM (CYP2C19), 6.27 μM (CYP2D6), 7.66 μM (CYP1A2) and 9.38 μM (CYP2E1), respectively. The data indicated that celastrol acted in different manners as an inhibitor of human cytochrome P450 isoforms, which showed that celastrol not only un-competitively inhibited the CYP1A2 and 2E1 activities, but also competitively inhibited the CYP2C19 and 2D6 activities with Ki values of 1.41, 2.29, 5.27 and 4.21 μM, respectively. Celastrol was also a mixed-type inhibitor of CYP3A4, with Ki and Kis values of 2.02 and 5.49 μM, respectively. 3. Celastrol has the potential to inhibit cytochrome P450 activities and may cause the herb-drug interactions. Therefore, the use of celastrol and its preparations with conventional medicines should thus be taken in to account.

Citing Articles

Optimization of a sensitive and reliable UPLC-MS/MS method to simultaneously quantify almonertinib and HAS-719 and its application to study the interaction with nicardipine.

Chen D, Chen J, Shen Y, Chen X, Xia H, Liu Y Pharm Biol. 2024; 62(1):874-881.

PMID: 39540617 PMC: 11565681. DOI: 10.1080/13880209.2024.2425648.


Potential Application of Plant-Derived Compounds in Multiple Sclerosis Management.

Woodfin S, Hall S, Ramerth A, Chapple B, Fausnacht D, Moore W Nutrients. 2024; 16(17).

PMID: 39275311 PMC: 11397714. DOI: 10.3390/nu16172996.


Inhibitory effect of napabucasin on arbidol metabolism and its mechanism research.

Nie J, Xia H, Liu Y, Yu Y, Xu R Front Pharmacol. 2023; 14:1292354.

PMID: 38094891 PMC: 10716843. DOI: 10.3389/fphar.2023.1292354.


Inhibitory mechanism of vortioxetine on CYP450 enzymes in human and rat liver microsomes.

Zhan Y, Wang A, Yu Y, Chen J, Xu X, Nie J Front Pharmacol. 2023; 14:1199548.

PMID: 37790811 PMC: 10544575. DOI: 10.3389/fphar.2023.1199548.


Differential effects of ketoconazole, fluconazole, and itraconazole on the pharmacokinetics of pyrotinib and .

Wang L, Wu F, Xu J, Wang Y, Fei W, Jiang H Front Pharmacol. 2022; 13:962731.

PMID: 36160438 PMC: 9490176. DOI: 10.3389/fphar.2022.962731.